OBJECTIVE: To compare activated protein C (aPC) sensitivity in 37 type I diabetic patients and 33 healthy control subjects. RESEARCH DESIGN AND METHODS: In this study, 37 type I diabetic patients and 33 healthy control subjects without personal or familial history of venous thrombosis and coagulation disorders, infections, intercurrent conditions, serum lupus anticoagulant, clinical cardiovascular complications, or drugs were examined. RESULTS: The aPC ratio (aPTT [activated partial thromboplastin time] with and without aPC) was significantly lower in the type I diabetic patients than in the control subjects (P = 0.005). CONCLUSIONS: These results suggest that the final steps of the protein C/S inhibiting system could be abnormal in type I diabetes.
OBJECTIVE: To compare activated protein C (aPC) sensitivity in 37 type I diabeticpatients and 33 healthy control subjects. RESEARCH DESIGN AND METHODS: In this study, 37 type I diabeticpatients and 33 healthy control subjects without personal or familial history of venous thrombosis and coagulation disorders, infections, intercurrent conditions, serum lupus anticoagulant, clinical cardiovascular complications, or drugs were examined. RESULTS: The aPC ratio (aPTT [activated partial thromboplastin time] with and without aPC) was significantly lower in the type I diabeticpatients than in the control subjects (P = 0.005). CONCLUSIONS: These results suggest that the final steps of the protein C/S inhibiting system could be abnormal in type I diabetes.